Ajinomoto Cambrooke, Inc.
Mary Susan Spears, MS, RD, CSP, LD is a Clinical Support Specialist at Cambrooke Therapeutics since July 2015. Prior to this role, Mary Susan served as a Clinical Dietitian at Children's Medical Center from October 2000 to May 2015, focusing on diet therapy management for children utilizing Ketogenic and Modified Atkins Diet therapies, as well as providing nutrition assessment and counseling for pediatric patients with neuromuscular disorders. Mary Susan also worked as a Clinical Dietitian at Sodexo from October 1994 to October 2000. Educational qualifications include a Master of Science in Human Nutrition from Texas Woman's University, a Dietetic Internship from the University of Iowa, and a Bachelor of Science in Foods, Nutrition, and Related Services from Texas Tech University.
This person is not in any offices
Ajinomoto Cambrooke, Inc.
Ajinomoto Cambrooke, Inc. formerly Cambrooke Therapeutics, Inc. (expansion of Cambrooke Foods) was founded in 2000 by Lynn and David Paolella, the parents of two children diagnosed with a rare disease called phenylketonuria (PKU). PKU is one of the few genetic diseases, which is managed almost entirely with nutritional intervention. The Paolellas’ goal in forming Cambrooke was simple - to develop improved nutritional therapeutic options for those with serious medical disorders. Today, Cambrooke produces medical formulas and foods for the management of a variety of medical conditions and we are continually innovating new nutritional options targeted at a wide array of diseases. Ajinomoto Cambrooke, Inc. - Leaders in Therapeutic Medical Nutrition. Cambrooke was the first medical foods company to launch a natural intact protein for the dietary management of phenylketonuria called Glytactin™ (modified glycomacropeptide). Cambrooke collaborates with academia and industry partners to transform early phase development projects in therapeutic nutrition into viable commercial products. Cambrooke employs scientific experts in the development, manufacturing and commercialization of nutritional therapeutics for patients with rare diseases. Cambrooke’s products are supported by clinical evidence for the nutritional management of medical needs before they are selected for commercialization. Cambrooke believes that both large and small patient populations are important when it comes to complex nutritional requirements.